3 Largest Private Hospital Group, Regional Hospital Network and National Pathology Chain Stocks With a Strong Future Roadmap: Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare
- October 23, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare: ROE of 10.7% to 20.5% and FY22 to FY26 revenue CAGR of 7.6% to 23.8%. Prices as of 22 Oct 2026.
Quick Answer
The three private hospital and pathology services stocks to watch are Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare. Their return on equity ranges from 10.7% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 23.8%. Apollo Hospitals Enterprise has the highest return on equity at 20.5%, while Krishna Institute of Medical Sciences has the fastest revenue growth at 23.8% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Private hospital and pathology services stocks let investors follow companies that treat patients and test samples across India. Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare cover the largest private hospital group, a regional hospital network and a national pathology chain.
This list covers three private hospital and pathology services stocks with complete current figures: Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Private Hospital and Pathology Services Stocks?
Private hospital and pathology services stocks are listed companies that run hospitals and diagnostic laboratories. Their earnings depend on bed capacity, occupancy, the mix of procedures and test volumes.
Private Hospital and Pathology Services Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | 7,604.5 | 110,757 | 51.0 | 59.6 | 20.5 | 0.90 |
| Krishna Institute of Medical Sciences | 668.55 | 28,495 | 146.5 | 59.6 | 10.7 | 1.89 |
| Metropolis Healthcare | 530.6 | 10,780 | 53.1 | 59.6 | 12.6 | 0.15 |
On valuation, Apollo Hospitals Enterprise and Metropolis Healthcare trade at a P/E below the industry P/E, while Krishna Institute of Medical Sciences trades above it, which reflects the growth the market already expects. Readers comparing private hospital and pathology services stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in private hospital and pathology services stocks can use the coming numbers to test whether growth is holding.
Why Do Private Hospital and Pathology Services Stocks Have a Strong Roadmap in India?
Private hospital and pathology services stocks have a strong roadmap in India because rising incomes, wider insurance cover and a preference for trusted providers are moving patients towards organised care.
- Insurance cover. More insured families choose organised hospitals for planned care.
- Integrated care. Hospitals, pharmacies and labs under one brand build patient loyalty.
- Test volumes. Regular health checks lift the number of tests per person.
Why Apollo Hospitals Enterprise Features Among These Private Hospital and Pathology Services Stocks
Among the private hospital and pathology services stocks on this list, Apollo Hospitals Enterprise is India’s largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.
Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.
Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.
Why Krishna Institute of Medical Sciences Features Among These Private Hospital and Pathology Services Stocks
Among the healthcare services company shares on this list, Krishna Institute of Medical Sciences, known as KIMS Hospitals, runs a network of multi-specialty hospitals in Telangana, Andhra Pradesh and other states, with strengths in cardiac, neuro and transplant care.
In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%.
Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6.
Roadmap: The company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Why Metropolis Healthcare Features Among These Private Hospital and Pathology Services Stocks
Among the three companies on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.
The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6.
Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore.
Roadmap: The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What to watch: Follow test volumes per patient and the pace at which newer regions turn profitable.
Apollo Hospitals Enterprise vs Krishna Institute of Medical Sciences vs Metropolis Healthcare on Key Financials
The table below sets the three private hospital and pathology services stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | 14,741 | 25,420 | 14.6% | 2,003 | 7.9% |
| Krishna Institute of Medical Sciences | 1,671 | 3,931 | 23.8% | 242 | 6.2% |
| Metropolis Healthcare | 1,246 | 1,671 | 7.6% | 191 | 11.4% |
Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Krishna Institute of Medical Sciences shows the fastest revenue growth with a 23.8% compound annual rate. A useful habit with private hospital and pathology services stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pathology lab operator stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Apollo Hospitals Enterprise | 5,882 | 7,092 | 20.6% |
| Krishna Institute of Medical Sciences | 879 | 1,196 | 36.1% |
| Metropolis Healthcare | 394 | 455 | 15.7% |
Key Risks to Check Before Investing in Private Hospital and Pathology Services Stocks
Every theme carries risks that deserve a check before any decision. For these private hospital and pathology services stocks, the main points are: Long-term healthcare services company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Ramp-up timing. New hospitals take time to reach stable utilisation.
- Doctor availability. Expert doctors are central to growth and hard to attract.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter private hospital and pathology services stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Private Hospital and Pathology Services Stocks
Private hospital and pathology services stocks reward investors who follow bed additions, occupancy and test volumes together. Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare each have a clear plan to widen their reach. Based on the 22 October 2026 close, Apollo Hospitals Enterprise trades at Rs 7,604.5, Krishna Institute of Medical Sciences at Rs 668.55 and Metropolis Healthcare at Rs 530.6. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these private hospital and pathology services stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track private hospital and pathology services stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are private hospital and pathology services stocks?
Ans. Private hospital and pathology services stocks are listed companies that run hospitals and diagnostic laboratories. Their earnings depend on bed capacity, occupancy, the mix of procedures and test volumes. This list looks at three of them, Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which private hospital and pathology services stocks are covered in this list?
Ans. This list covers Apollo Hospitals Enterprise, Krishna Institute of Medical Sciences and Metropolis Healthcare. Based on the 22 October 2026 close, Apollo Hospitals Enterprise traded at Rs 7,604.5, Krishna Institute of Medical Sciences at Rs 668.55 and Metropolis Healthcare at Rs 530.6. Their return on equity ranges from 10.7% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 23.8%.
Why do private hospital and pathology services stocks have a strong future roadmap in India?
Ans. Private hospital and pathology services stocks have a strong roadmap in India because rising incomes, wider insurance cover and a preference for trusted providers are moving patients towards organised care. The main drivers are as follows. Insurance cover. More insured families choose organised hospitals for planned care. Integrated care. Hospitals, pharmacies and labs under one brand build patient loyalty. Test volumes. Regular health checks lift the number of tests per person. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Apollo Hospitals Enterprise performed financially?
Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
How has Krishna Institute of Medical Sciences performed financially?
Ans. Revenue rose from Rs 1,671 crore in FY22 to Rs 3,931 crore in FY26, a compound annual growth rate of 23.8%. Net profit for FY26 was Rs 242 crore, a net margin of 6.2%. In the June 2026 quarter, revenue grew 36.1% year on year to Rs 1,196 crore. The company has a return on equity of 10.7%, a debt to equity ratio of 1.89 and a market capitalisation of Rs 28,495 crore. The stock trades at a P/E of 146.5, above the industry P/E of 59.6. Looking ahead, the company is adding beds in existing clusters and opening hospitals in new cities across southern and central India. Rising insurance cover and demand for advanced procedures support growth in patient volumes.
How has Metropolis Healthcare performed financially?
Ans. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What risks should investors check before buying private hospital and pathology services stocks?
Ans. Investors should check a few risks before buying private hospital and pathology services stocks. Ramp-up timing. New hospitals take time to reach stable utilisation. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of private hospital and pathology services stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.